SSRIs in the course of COVID-19 pneumonia: Evidence of effectiveness of antidepressants on acute inflammation. A retrospective study.
COVID-19
IL-6
SARS-Cov 2
antidepressants
inflammation
pneumonia
Journal
Human psychopharmacology
ISSN: 1099-1077
Titre abrégé: Hum Psychopharmacol
Pays: England
ID NLM: 8702539
Informations de publication
Date de publication:
07 Dec 2023
07 Dec 2023
Historique:
revised:
07
11
2023
received:
29
07
2023
accepted:
08
11
2023
medline:
7
12
2023
pubmed:
7
12
2023
entrez:
7
12
2023
Statut:
aheadofprint
Résumé
Relationships between inflammation and mood have been observed in terms of pro-inflammatory effects induced by depressive conditions and, in parallel, by an antidepressant-induced favorable effect on the recovery of inflammatory states. Selective serotonin reuptake inhibitor (SSRI) drugs were hypothesized to improve the prognosis of COVID-19 pneumonia, a typical acute inflammation, in terms of decreased mortality rate and pro-inflammatory cytokine serum levels. The medical records of COVID-19 pneumonia inpatients at Careggi University Hospital (Florence) were analyzed for prognosis and Interleukin 6 (IL-6) after admission for over a period of 22 months. Medical records of patients treated at admission and not discontinued until discharge with an SSRI or with vortioxetine were identified. Two groups, one treated with antidepressants, the other not treated, were evaluated according to the mentioned parameters. Multiple linear regression and logistic regression were performed. The entire sample composed of 1236 records (recovered patients 77.1%, deceased patients 22.9%). The treated group (n = 107) had a better prognosis than the untreated group in spite of age and comorbidity both being greater than in the untreated group. Correspondingly, IL-6 levels in the treated group were significantly lower (p < 0.01) than the levels in the untreated group, in every comparison. Outcomes of this study support the hypothesis of the favorable influence of some antidepressants on the prognosis of COVID-19, possibly mediated by IL-6 modulation. Reduction in acute inflammation induced by the action of antidepressants was confirmed.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2887Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Berk, M., Wadee, A. A., Kuschke, R. H., & O'Neill-Kerr, A. (1997). Acute phase proteins in major depression. Journal of Psychosomatic Research, 43(5), 529-534. https://doi.org/10.1016/s0022-3999(97)00139-6
Beurel, E., Toups, M., & Nemeroff, C. B. (2020). The biredirectional relationship of depression and inflammation: Double trouble. Neuron, 107(2), 234-256. https://doi.org/10.1016/j.neuron.2020.06.002
Bonnet, U., Juckel, G., Scherbaum, N., Simmaco, M., Ferracuti, S., Lamis, D. A., & Kuhn, J. (2021). Are persons treated with antidepressants and/or antipsychotics possibly better protected against severe COVID-19? Pharmacopsychiatry, 54(3), 142-143. https://doi.org/10.1055/a-1408-8298
Charlson, M. E., Carrozzino, D., Guidi, J., & Patierno, C. (2022). Charlson comorbidity Index: A critical review of clinimetric properties. Psychotherapy and Psychosomatics, 91(1), 8-35. https://doi.org/10.1159/000521288
Clelland, C. L., Ramiah, K., Steinberg, L., & Clelland, J. D. (2021). Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort. BJPsych Open, 8(1), e6. https://doi.org/10.1192/bjo.2021.1053
Coomes, E. A., & Haghbayan, H. (2020). Interleukin-6 in COVID-19: A systematic review and meta-analysis. Reviews in Medical Virology, 30(6), 1-9. https://doi.org/10.1002/rmv.2141
Costanzo, E. S., Lutgendorf, S. K., Sood, A. K., Anderson, B., Sorosky, J., & Lubaroff, D. M. (2005). Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer, 104(2), 305-313. https://doi.org/10.1002/cncr.21147
Creeden, J. F., Imami, A. S., Eby, H. M., Gillman, C., Becker, K. N., Reigle, J., Andari, E., Pan, Z. K., O’Donovan, S. M., McCullumsmith, R. E., & McCullumsmith, C. B. (2021). Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection. Biomedicine & Pharmacotherapy, 138, 111437. https://doi.org/10.1016/j.biopha.2021.111437
Cyranowski, J. M., Marsland, A. L., Bromberger, J. T., Whiteside, T. L., Chang, Y., & Matthews, K. A. (2007). Depressive symptoms and production of proinflammatory cytokines by peripheral blood mononuclear cells stimulated in vitro. Brain, Behavior, and Immunity, 21(2), 229-237. https://doi.org/10.1016/j.bbi.2006.07.005
Dhabhar, F. S., Burke, H. M., Epel, E. S., Mellon, S. H., Rosser, R., Reus, V. I., & Wolkowitz, O. M. (2009). Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. Journal of Psychiatric Research, 43(11), 962-969. https://doi.org/10.1016/j.jpsychires.2009.05.010
Dinan, T. G. (2009). Inflammatory markers in depression. Current Opinion in Psychiatry, 22(1), 32-36. https://doi.org/10.1097/YCO.0b013e328315a561
Dionisie, V., Filip, G. A., Manea, M. C., Manea, M., & Riga, S. (2021). The anti-inflammatory role of SSRI and SNRI in the treatment of depression: A review of human and rodent research studies. Inflammopharmacology, 29(1), 75-90. https://doi.org/10.1007/s10787-020-00777-5
Fei, L., Santarelli, G., D'Anna, G., Moretti, S., Mirossi, G., Patti, A., et al. (2021). Can SSRI/SNRI antidepressants decrease the 'cytokine storm' in the course of COVID-19 pneumonia? Panminerva Medica. https://doi.org/10.23736/S0031-0808.21.04436-0
Foletto, V. S., da Rosa, T. F., Serafin, M. B., & Hörner, R. (2022). Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: Prospects for use. European Journal of Clinical Pharmacology, 78(10), 1601-1611. https://doi.org/10.1007/s00228-022-03372-5
Fred, S. M., Kuivanen, S., Ugurlu, H., Cabrera Casarotto, P., Levanov, L., Saksela, K., Vapalahti, O., & Castrén, E. (2022). Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine shows antiviral activity against the novel variants in vitro. Frontiers in Pharmacology, 12, 755600. https://doi.org/10.3389/fphar.2021.755600
Fritz, B. A., Hoertel, N., Lenze, E. J., Jalali, F., & Reiersen, A. M. (2022). Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2. Translational Psychiatry, 12(1), 341. https://doi.org/10.1038/s41398-022-02109-3
Glebov, O. O. (2021). Low-dose fluvoxamine modulates endocytic trafficking of SARS-CoV-2 spike protein: A potential mechanism for anti-COVID-19 protection by antidepressants. Frontiers in Pharmacology, 12, 787261. https://doi.org/10.3389/fphar.2021.787261
Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016). A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression. Molecular Psychiatry, 21(12), 1696-1709. https://doi.org/10.1038/mp.2016.3
Haapakoski, R., Mathieu, J., Ebmeier, K. P., Alenius, H., & Mika Kivimäki, M. (2015). Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain, Behavior, and Immunity, 49, 206-215. Epub 2015 Jun 9. https://doi.org/10.1016/j.bbi.2015.06.001
Hashimoto, K. (2023). Overview of the potential use of fluvoxamine for COVID-19 and long COVID. Discover Mental Health, 3(1), 9. https://doi.org/10.1007/s44192-023-00036-3
Hashimoto, Y., Suzuki, T., & Hashimoto, K. (2022). Mechanisms of action of fluvoxamine for COVID-19: A historical review. Molecular Psychiatry, 27(4), 1898-1907. https://doi.org/10.1038/s41380-021-01432-3
Hickie, I., & Lloyd, A. (1995). Are cytokines associated with neuropsychiatric syndromes in humans? International Journal of Immunopharmacology, 17(8), 677-683. https://doi.org/10.1016/0192-0561(95)00054-6
Hoertel, N., Sánchez-Rico, M., Gulbins, E., Kornhuber, J., Carpinteiro, A., Abellán, M., de la Muela, P., Vernet, R., Beeker, N., Neuraz, A., Delcuze, A., Alvarado, J. M., Cougoule, C., Meneton, P., & Limosin, F. (2022). Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: An observational multicenter study. Translational Psychiatry, 12(1), 90. https://doi.org/10.1038/s41398-022-01804-5
Hoertel, N., Sánchez-Rico, M., Vernet, R., Beeker, N., Jannot, A. S., Neuraz, A., Salamanca, E., Paris, N., Daniel, C., Gramfort, A., Lemaitre, G., Bernaux, M., Bellamine, A., Lemogne, C., Airagnes, G., Burgun, A., & Limosin, F. (2021). Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: Results from an observational study. Molecular Psychiatry, 26(9), 5199-5212. https://doi.org/10.1038/s41380-021-01021-4
Howren, M. B., Lamkin, D. M., & Suls, J. (2009). Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosomatic Medicine, 71(2), 171-186. Epub 2009 Feb 2. https://doi.org/10.1097/PSY.0b013e3181907c1b
Jacobson, C. M., Rosenfeld, B., Pessin, H., & Breitbart, W. (2008). Depression and IL-6 blood plasma concentrations in advanced cancer patients. Psychosomatics, 49(1), 64-66. https://doi.org/10.1176/appi.psy.49.1.64
Khandaker, G. M., Rebecca, M. P., Zammit, S., Lewis, G., & Jones, P. B. (2014). Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: A population-based longitudinal study. JAMA Psychiatry, 71(10), 1121-1128. https://doi.org/10.1001/jamapsychiatry.2014.1332
Kronfol, Z. (2002). Immune dysregulation in major depression: A critical review of existing evidence. International Journal of Neuropsychopharmacology, 5(4), 333-343. https://doi.org/10.1017/S1461145702003024
Kubera, M., Obuchowicz, E., Goehler, L., Brzeszcz, J., & Maes, M. (2011). In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Progress In Neuro-Psychopharmacology & Biological Psychiatry, 35(3), 744-759. https://doi.org/10.1016/j.pnpbp.2010.08.026
Lamers, F., Milaneschi, Y., Smit, J. H., Schoevers, R. A., Gayle Wittenberg, G., & Penninx, B. W. J. H. (2019). Longitudinal association between depression and inflammatory markers: Results from The Netherlands study of depression and anxiety. Biological Psychiatry, 85(10), 829-837. Epub 2019 Jan 9. https://doi.org/10.1016/j.biopsych.2018.12.020
Leisman, D. E., Ronner, L., Pinotti, R., Taylor, M. D., Sinha, P., Calfee, C. S., Hirayama, A. V., Mastroiani, F., Turtle, C. J., Harhay, M. O., Legrand, M., & Deutschman, C. S. (2020). Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respiratory Medicine, 8(12), 1233-1244. https://doi.org/10.1016/S2213-2600(20)30404-5
Leonard, B. E. (2001). The immune system, depression and the action of antidepressants. Progress In Neuro-Psychopharmacology & Biological Psychiatry, 25(4), 767-780. https://doi.org/10.1016/s0278-5846(01)00155-5
Licinio, J., & Wong, M. L. (1999). The role of inflammatory mediators in the biology of major depression: Central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Molecular Psychiatry, 4(4), 317-327. https://doi.org/10.1038/sj.mp.4000586
Lutgendorf, S. K., Garand, L., Buckwalter, K. C., Reimer, T. T., Hong, S. Y., & Lubaroff, D. M. (1999). Life stress, mood disturbance, and elevated interleukin-6 in healthy older women. J Gerontol A Biol Sci Med Sci, 54(9), M434-M439. https://doi.org/10.1093/gerona/54.9.m434
Maes, M., Meltzer, H. Y., Bosmans, E., Bergmans, R., Vandoolaeghe, E., Ranjan, R., & Desnyder, R. (1995). Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. Journal of Affective Disorders, 34(4), 301-309. https://doi.org/10.1016/0165-0327(95)00028-l
Mahdi, M., Hermán, L., Réthelyi, J. M., & Bálint, B. L. (2022). Potential role of the antidepressants fluoxetine and fluvoxamine in the treatment of COVID-19. International Journal of Molecular Sciences, 23(7), 3812. https://doi.org/10.3390/ijms23073812
Marques-Deak, A. H., Lotufo Neto, F., Dominguez, W. V., Solis, A. C., Kurcgant, D., Sato, F., Ross, J., & Prado, E. (2007). Cytokine profiles in women with different subtypes of major depressive disorder. Journal of Psychiatric Research, 41(1-2), 152-159. https://doi.org/10.1016/j.jpsychires.2005.11.003
Mas, M., García-Vicente, J. A., Estrada-Gelonch, A., Pérez-Mañá, C., Papaseit, E., Torrens, M., & Farré, M. (2022). Antidepressant drugs and COVID-19: A review of basic and clinical evidence. Journal of Clinical Medicine, 11(14), 4038. https://doi.org/10.3390/jcm11144038
Mazza, M. G., Palladini, M., Poletti, S., & Benedetti, S. (2022). Post-COVID-19 depressive symptoms: Epidemiology, pathophysiology, and pharmacological treatment. CNS Drugs, 36(7), 681-702. https://doi.org/10.1007/s40263-022-00931-3
McDonald, E. M., Mann, A. H., & Thomas, H. C. (1987). Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet, 2(8569), 1175-1178. https://doi.org/10.1016/s0140-6736(87)91319-5
Meyer, N. J., Gattinoni, L., & Calfee, C. S. (2021). Acute respiratory distress syndrome. Lancet, 398(10300), 622-637. https://doi.org/10.1016/S0140-6736(21)00439-6
Min, K. H., Kim, T. H., Oh, S. J., Kim, W., & Lee, K. E. (2022). COVID-19 prognosis in association with antidepressant use. Pharmacopsychiatry, 55(4), 220-227. https://doi.org/10.1055/a-1842-7859
Mueller, J. K., Riederer, P., & Müller, W. E. (2022). Neuropsychiatric drugs against COVID-19: What is the clinical evidence? Pharmacopsychiatry, 55(1), 7-15. https://doi.org/10.1055/a-1717-2381
Mulugeta, A., Zhou, A., King, C., & Hyppönen, E. (2020). Association between major depressive disorder and multiple disease outcomes: A phenome-wide mendelian randomisation study in the UK biobank. Molecular Psychiatry, 25(7), 1469-1476. https://doi.org/10.1038/s41380-019-0486-1
Murru, A., Manchia, M., Hajek, T., Nielsen, R. E., Rybakowski, J. K., Sani, G., Schulze, T. G., Tondo, L., & Bauer, M. (2020). Lithium's antiviral effects: A potential drug for COVID-19 disease? International Journal of Bipolar Disorders, 8(1), 21. https://doi.org/10.1186/s40345-020-00191-4
Oskotsky, T., Maric, I., Tang, A., Oskotsky, B., Wong, R. J., Aghaeepour, N., Sirota, M., & Stevenson, D. K. (2021). Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. JAMA Network Open, 4(11), e2133090. https://doi.org/10.1001/jamanetworkopen.2021.33090
Osservatorio Nazionale sull’impiego dei Medicinali. (2022). L’uso dei Farmaci in Italia. Rapporto Nazionale Anno 2021. Agenzia Italiana del Farmaco.
Parohan, M., Yaghoubi, S., Seraji, A., Javanbakht, M. H., Sarraf, P., & Djalali, M. (2020). Risk factors for mortality in patients with coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of observational studies. The Aging Male, 23(5), 1416-1424. https://doi.org/10.1080/13685538.2020.1774748
Pfefferbaum, B., & North, C. S. (2020). Mental health and the COVID-19 pandemic. New England Journal of Medicine, 383(6), 510-512. https://doi.org/10.1056/nejmp2008017
Rauchman, S. H., Mendelson, S. G., Rauchman, C., Kasselman, L. J., Pinkhasov, A., & Reiss, A. B. (2021). Ongoing use of SSRIs does not alter outcome in hospitalized COVID-19 patients: A retrospective analysis. Journal of Clinical Medicine, 11(1), 70. https://doi.org/10.3390/jcm11010070
Schlatter, J., Ortuno, F., & Cervera-Enguix, S. (2001). Differences in interleukins' patterns between dysthymia and major depression. European Psychiatry, 16(5), 317-319. https://doi.org/10.1016/s0924-9338(01)00585-5
Smith, R. S. (1991). The macrophage theory of depression. Medical Hypotheses, 35(4), 298-306. https://doi.org/10.1016/0306-9877(91)90272-z
Stauning, M. A., Gür, D. J., Torp-Pedersen, C., & Tingleff, J. (2023). COVID-19 mortality among selective serotonin reuptake inhibitor users - results from a nationwide cohort. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2023.04.028
Stewart, J. C., Rand, K. L., Muldoon, M. F., & Kamarck, T. W. (2009). A prospective evaluation of the directionality of the depression-inflammation relationship. Brain, Behavior, and Immunity, 23(7), 936-944. https://doi.org/10.1016/j.bbi.2009.04.011
Subramanian, A., Nirantharakumar, K., Hughes, S., Myles, P., Williams, T., Gokhale, K. M., Taverner, T., Chandan, J. S., Brown, K., Simms-Williams, N., Shah, A. D., Singh, M., Kidy, F., Okoth, K., Hotham, R., Bashir, N., Cockburn, N., Lee, S. I., Turner, G. M., & Haroon, S. (2022). Symptoms and risk factors for long COVID in non-hospitalized adults. Nature Medicine, 28(8), 1706-1714. https://doi.org/10.1038/s41591-022-01909-w
Ting, E. Y., Yang, C. A., & Tsai, S. J. (2020). Role of interleukin-6 on depressive disorder. International Journal of Molecular Sciences, 21(6), 2194. https://doi.org/10.3390/ijms21062194
Visos-Varela, I., Zapata-Cachafeiro, M., Piñeiro-Lamas, M., Carracedo-Martínez, E., Saez, M., Herdeiro, M. T., Figueiras, A., & Salgado-Barreira, Á. (2023). Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: A population-based study. European Neuropsychopharmacology, 71, 96-108. Online ahead of print. https://doi.org/10.1016/j.euroneuro.2023.03.011
Zheng, W., Sun, H. L., Cai, H., Zhang, Q., Ng, C. H., & Yu-Xiang, Y. T. (2022). Antidepressants for COVID-19: A systematic review. Journal of Affective Disorders, 307, 108-114. https://doi.org/10.1016/j.jad.2022.03.059